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Introduction
Much has been publicized recently about the expansion 
of hospital- and community-based infections caused by 
Gram-positive bacteria, especially those caused by 
vancomycin-resistant enterococci (VRE) and methicillin-
resistant Staphylococcus aureus (MRSA) [1]. However, a 
second, but potentially more important, threat to critical 
care is that caused by the multidrug-resistant Gram-
negative bacteria. Th  e response of the pharmaceutical 
companies over the past decade has been to design new 
drugs that can treat VRE and both hospital- and 
community-acquired MRSA infections [2]. However, 
what is lacking from the current pharmaceutical arsenal 
are drugs to treat multidrug-resistant Gram-negative 
infections in the hospital setting [3]. Because β-lactam 
antibiotics have long been a component in the treatment 
regimen for serious nosocomial infections, any threat to 
their eﬃ   cacy must be examined closely.
Among the β-lactam antibiotics of clinical utility for 
the treatment of infections caused by susceptible Gram-
negative bacteria are penicillins such as amoxicillin, oral 
cephalosporins such as cefpodoxime and cefuroxime 
axetil, parenteral cephalosporins such as cefepime and 
ceftri  axone, and the carbapenems such as doripenem, 
erta  penem, imipenem, and meropenem. Combinations of 
penicillins with β-lactamase inhibitors also play promi  nent 
therapeutic roles, with amoxicillin-clavulanic acid being a 
major factor in the treatment of community infections and 
piperacillin-tazobactam being important for serious 
hospital-acquired infections. In this review, the role of β-
lactamases will be discussed as a major cause of resistance 
to these safe and widely prescribed drugs.
Infections associated with Gram-negative bacteria
Infections caused by Gram-positive bacteria represented 
the majority of serious infections prior to the late 1950s. 
Th  us, it is not surprising that the increased use of 
penicillins to treat the associated diseases caused β-
lactam resistance to arise in the clinical setting, ﬁ  rst in 
the staphylococci and then in Gram-negative bacteria. 
When penicillins lost their utility as monotherapy for 
most disease states, penicillins and cephalosporins that 
were more potent were developed in an eﬀ  ort to retain 
the favorable clinical properties of the β-lactam anti-
biotics. In addition to predictable eﬃ   cacy in a number of 
clinical indications, these agents have continued to 
Abstract
Multidrug resistance has been increasing among 
Gram-negative bacteria and is strongly associated 
with the production of both chromosomal- and 
plasmid-encoded β-lactamases, whose number now 
exceeds 890. Many of the newer enzymes exhibit 
broad-spectrum hydrolytic activity against most classes 
of β-lactams. The most important plasmid-encoded 
β-lactamases include (a) AmpC cephalosporinases 
produced in high quantities, (b) the expanding families 
of extended-spectrum β-lactamases such as the 
CTX-M enzymes that can hydrolyze the advanced-
spectrum cephalosporins and monobactams, and 
(c) carbapenemases from multiple molecular classes 
that are responsible for resistance to almost all 
β-lactams, including the carbapenems. Important 
plasmid-encoded carbapenemases include (a) the 
KPC β-lactamases originating in Klebsiella pneumoniae 
isolates and now appearing worldwide in pan-resistant 
Gram-negative pathogens and (b) metallo-β-lactamases 
that are produced in organisms with other deleterious 
β-lactamases, causing resistance to all β-lactams 
except aztreonam. β-Lactamase genes encoding 
these enzymes are often carried on plasmids that bear 
additional resistance determinants for other antibiotic 
classes. As a result, some infections caused by Gram-
negative pathogens can now be treated with only a 
limited number, if any, antibiotics. Because multidrug 
resistance in Gram-negative bacteria is observed in both 
nosocomial and community isolates, eradication of 
these resistant strains is becoming more diffi   cult.
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makes them attractive therapeutic agents.
As shown in Table 1, the most common families of β-
lactams that are used to treat infections caused by Gram-
negative pathogens include extended-spectrum cephalo-
sporins such as ceftriaxone and cefepime, penicillin-β-
lactamase inhibitor combinations such as amoxicillin-
clavulanic acid and piperacillin-tazobactam, and the 
carba  penems [4]. Infection types range from uncom  pli-
cated community-acquired infections such as otitis media 
to serious nosocomial infections, including ventilator-
associated pneumonia. Orally administered β-lactams 
such as amoxicillin-clavulanic acid and the oral cephalo-
sporins ceﬁ  xime, cefpodoxime, and cefuroxime axetil are 
recommended for community infections. For nosocomial 
infections that are not resistant to cephalosporins, 
parenteral drugs that may be eﬀ   ective include the 
injectable penicillin-β-lactamase inhibitor combinations 
and cephalosporins. Carbapenems are often reserved to 
treat the most serious infections caused by many 
multidrug-resistant pathogens as they are most able to 
escape at least some of the common β-lactam resistance 
mechanisms that aﬀ   ect the other β-lactam families. 
However, the continued use of these antibiotics for 
important disease states has maintained the pressure on 
many pathogenic and commensal bacteria to retain 
enzymatic inactivation mechanisms that render 
penicillins ineﬀ   ective in many disease states. Th  is 
pressure has resulted in a surge in β-lactam resistance 
due to inactivating enzymes, particularly in Gram-
negative pathogens.
Background of β-lactamase resistance
In 1940, an enzyme produced by a strain of Bacillus coli, 
now known as Escherichia coli, was shown to destroy the 
ability of penicillin to kill bacterial cells [5]. Th  is ﬁ  rst 
report of β-lactamase activity occurred before wide-
spread use of penicillin, demonstrating the presence of β-
lactam-inactivating enzymes in the natural environment. 
Th   ese enzymes have the ability to hydrolyze the β-lactam 
chemical bond that distinguishes β-lactam antibiotics 
from other antibacterial agents, thereby rendering the 
molecules incapable of killing bacteria.
Today, over 890 unique β-lactamases have been 
identi  fied in naturally occurring bacterial isolates [6,7]. 
These enzymes have been separated into groups, 
either accord  ing to the amino acid sequences of the 
enzymes or according to their inactivating properties 
for different classes of β-lactams. The molecular 
classification scheme divides β-lactamases into four 
classes based on the amino acid sequences of the 
proteins [8-10], whereas numeri  cally more functional 
groups have been assigned based on the hydrolysis and 
inhibition profiles of the enzymes [7,10,11]. The major 
functional groups of current clinical importance are 
shown in Table 2, where enzyme groups are commonly 
named according to the most important class of β-
lactam that is inactivated. Correlations between the 
Table 1. Common β-lactam antibiotics that may be used as monotherapy to treat infections caused by Gram-negative 
bacteria
Infection type  Phenotype  Possible β-lactam antibioticsa,b
Bacterial meningitis  Wild-type  Cefotaxime or ceftriaxone, cefepime, meropenem
Intra-abdominal Wild-type  Amoxicillin-clavulanic  acidc, piperacillin-tazobactam, ticarcillin-clavulanic acid, 
   cefoxitin,  cefotetan
 ESBL-producing  Carbapenemsd
Osteomyelitis Wild-type  Ceftazidime,  cefepime
Otitis media  Wild-type  Amoxicillin ± clavulanic acidc, cefdinirc, cefpodoximec, cefprozilc, cefuroxime axetilc, 
   ceftriaxone 
Lower respiratory infections   Wild-type  Amoxicillin-clavulanic acidc, piperacillin-tazobactam, ticarcillin-clavulanic acid, 
and pneumonia    aztreonam, cefdinirc, cefpodoximec, cefprozilc, cefuroxime axetilc, cefepime, 
    cefotaxime, ceftriaxone, ceftazidime
 ESBL-producing  Carbapenems
Gonorrhea Non-β-lactamase-producing  Penicillin  G
 β-lactamase-producing  Cefi   ximec, cefpodoximec, ceftriaxone, cefotaxime, cefuroxime
Skin and skin structure  Wild-type  Carbapenems
    Ampicillin-sulbactam, piperacillin-tazobactam, ticarcillin-clavulanic acid
Urinary tract (complicated)  Wild-type  Ampicillin-sulbactam, piperacillin-tazobactam, ticarcillin-clavulanic acid, ceftriaxone
 ESBL-producing  Carbapenems
aAntibiotics listed are based on those recommended in the 2009 Sanford Guide [4], assuming that the causative Gram-negative bacteria are susceptible to these 
agents. bAgents are dosed intravenously unless otherwise noted. cOral dosing. dCarbapenems for infections caused by Enterobacteriaceae include doripenem, 
ertapenem, imipenem, and meropenem. For infections caused by Pseudomonas aeruginosa, ertapenem should not be used. ESBL, extended-spectrum β-lactamase.
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in this compilation.
Descriptions of β-lactamase groups
Cephalosporinases
Group 1/Class C cephalosporinases are among the most 
abundant β-lactamases on the basis of the number of 
organisms that produce these enzymes. Th  ese cephalo-
sporinases, frequently named as species-speciﬁ  c AmpC 
enzymes, are often found in most Enterobacteriaceae as 
chromosomal enzymes. At low production levels, they 
can abolish the antibacterial activity of cephalosporins 
and can also demonstrate inactivating capabilities toward 
other β-lactams, especially when produced at high levels. 
Th   ese enzymes are generally present at a low (basal) level 
but may be induced to high levels in the presence of 
selected inducing agents such as amoxicillin or clavulanic 
acid. Cephalosporinases may also be produced at very 
high levels in the absence of an inducer, in a ‘derepressed’ 
state. Th   is has been reported to occur after selection of 
stable mutants during therapy with broad-spectrum 
cephalosporins, but not cefepime [12,13]. Th  ese  mutants 
often arise as a result of a multistep process, with elevated 
cephalosporin MICs (in the high susceptible or inter-
mediate range) observed in those organisms with im-
paired permeability characteristics prior to selection of 
high-level AmpC mutants that are fully resistant [14].
Treatment of organisms producing an inducible AmpC 
cephalosporinase has created some controversy. Although 
a group of investigators has recommended that any 
AmpC-inducible Enterobacteriaceae be regarded as 
resistant to all third-generation cephalosporins [13], the 
clinical data supporting this recommendation are mixed 
[14]. Studies have indicated that the selection of resistant 
Enterobacter spp. has ranged as high as 19% in a 1991 
study (6/31), with higher rates observed in patients with 
bacteremia [15], but more recent studies have not corro-
borated those observations [12]. For example, in an 
18-month study (2005-2006) of 732 patients infected 
with Enterobacteriaceae capable of producing AmpC β-
lactamases,  treatment with broad-spectrum cephalo-
sporins resulted in resistance in 5% (11/218) of the 
patients compared with 0% (0/20) of the patients treated 
with cefepime, with the emergence of resistance being 
more frequent in Enterobacter spp. [12].
Th   e suggestion has been made that therapeutic 
decisions be made on the basis of speciﬁ  c cephalosporin 
MICs rather than on the presence of an inducible AmpC 
enzyme [14]. Th  is year, the Clinical and Laboratory 
Standards Institute (Wayne, PA, USA) lowered suscep-
tibility breakpoints for cefotaxime, ceftriaxone, and 
ceftazidime against the Enterobacteriaceae [16]. Lower 
breakpoints should help to decrease the number of 
‘susceptible’ isolates that may be likely to emerge as 
resistant strains following therapy with broad-spectrum 
cephalosporins but will allow cephalosporins to be used 
against highly susceptible organisms. Th  e new cephalo-
sporin breakpoints will also classify as resistant those 
ESBL-producing Enterobacteriaceae that will not respond 
pharmacodynamically to approved therapeutic doses, 
thereby reducing the need for speciﬁ  c ESBL testing other 
than for epidemiological purposes [16].
Plasmid-encoded AmpC cephalosporinases closely 
related in sequence to chromosomal AmpC enzymes from 
Enterobacter cloacae, Citrobacter freundii, or Aero monas 
spp. also appear in Enterobacteriaceae in organisms that 
produce at least one other β-lactamase [17]. Although 
some of the plasmid-encoded AmpC enzymes are 
inducible, most of the enzymes are produced at much 
higher levels than seen for basal AmpC cephalo  sporinases, 
similar to isolates with derepressed AmpC enzymes [17].
Penicillinases
Common penicillinases (functional group 2b, molecular 
class A) include the SHV-1 enzyme in Klebsiella pneumo-
niae and the TEM-1 β-lactamase found in many strains 
Table 2. Major groups of β-lactamases in Gram-negative bacteria that threaten the role of β-lactam antibiotics
                                                                                                β-Lactams to which resistance is conferred
Functional Molecular
groupa classb Common  name  Primaryc Secondaryd
1  C  Cephalosporinase  Penicillins, cephalosporins  Carbapenems, monobactams
2b  A  Penicillinase  Penicillins, early cephalosporins  β-lactamase inhibitor combinations
2be  A  Extended-spectrum   Penicillins, cephalosporins, monobactams, 
    β-lactamase  β-lactamase inhibitor combinations  None
2d  D  Cloxacillinase  Penicillins, including oxacillin and cloxacillin  None
2df  D  Carbapenemase  Carbapenems and other β-lactams  None
2f  A  Carbapenemase  All current β-lactams  None
3  B  Metallo-β-lactamase  All β-lactams except monobactams  None
aClassifi  cation based on Bush, Jacoby, and Medeiros [11] and Bush and Jacoby [7]. bClassifi  ed according to primary amino acid sequence [8-10]. cβ-lactams that are 
resistant solely as a function of β-lactamase production. dβ-lactams that are resistant as a function of β-lactamase production, usually at high levels, in combination 
with effl   ux or porin modifi  cations.
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[19]. Th  ese two enzymes occurred in high prevalence 
among the Enterobacteriaceae prior to the introduction 
of the broad-spectrum cephalosporins such as cefotaxime 
and ceftazidime [20,21]. Th  e group 2b enzymes are 
readily inhibited by clavulanic acid, sulbactam, and 
tazobactam [11]. As a result, infections caused by 
organisms producing a single penicillinase can be readily 
treated with a β-lactamase inhibitor combination such as 
amoxicillin-clavulanic acid, ampicillin-sulbactam, or 
piperacillin-tazobactam.
Extended-spectrum β-lactamases
Particularly worrisome β-lactamases are found among 
the extended-spectrum β-lactamases, or ESBLs (func-
tional group 2be or molecular class A). Th  ese enzymes 
were recognized shortly after the introduction of ‘β-
lactamase-stable’ cephalosporins and aztreonam. ESBLs 
were initially identiﬁ  ed as variants of the common SHV-1 
or TEM-1 β-lactamase, often diﬀ  ering from the parent 
enzymes by only one or two amino acids. After their 
recognition in the late 1980s concomitantly in Europe 
[22] and the US [23,24], they became associated with 
major outbreaks of cephalosporin-resistant infections 
caused by ESBL-producing E. coli and K. pneumoniae 
[22,25]. Th  e genes that coded for these enzymes were 
generally found on plasmids that conferred resistance to 
multiple antibiotic classes and that were readily 
transferable among species [26]. Even during the ﬁ  rst 
reported outbreaks, other Enterobacteriaceae such as 
C.  freundii, Enterobacter aerogenese, and Serratia 
marcescens were identiﬁ  ed as ESBL producers [27].
ESBLs are still associated with major outbreaks of β-
lactam resistance. However, the early SHV and TEM 
variants have been largely replaced by the CTX-M family 
of ESBLs. Th  e  ﬁ  rst two CTX-M enzymes were identiﬁ  ed 
at approximately the same time in the early 1990s in 
western Europe and South America in individual clinical 
isolates [28,29]. Within a decade, the CTX-M β-lacta-
mases became the predominant ESBL family in many 
medical centers such that they have largely replaced most 
of the TEM- and SHV-derived ESBLs throughout the 
world [30-32].
CTX-M enzymes were particularly slow to emerge in 
the US [33] but have recently begun to dominate the 
ESBL populations of some US health centers [34]. Th  e 
MYSTIC (Meropenem Yearly Susceptibility Test Informa-
tion Collection) surveillance study of 2007 identiﬁ  ed 
CTX-M genes in 80% of the US medical centers that 
reported ESBL-producing isolates in their survey [35]. 
Th  e early CTX-M-producing isolates were fre  quently 
resistant to cefotaxime and ceftriaxone but susceptible to 
ceftazidime because of a strong preference for hydrolysis 
of the former cephalosporins. However, some members 
of the CTX-M family demonstrate high hydrolysis rates 
for all of the extended-spectrum cephalosporins as a 
result of single amino acid mutations, resulting in 
complete cephalosporin resistance in all of the producing 
pathogens [36,37]. It is possible that regional diﬀ  erences 
in the emergence of the CTX-M family were due to 
localized preferences for therapeutic regimens employing 
cefotaxime or ceftriaxone in Europe and South America 
compared with more frequent use of ceftazidime in the 
US and Canada.
OXA β-lactamases
Th  e ‘oxacillinase’ family of β-lactamases, the OXA 
enzymes, was originally named to reﬂ  ect the ability to 
hydrolyze oxacillin (or cloxacillin) [19]. Recently, a highly 
important subgroup of the OXA enzymes was identiﬁ  ed 
as a causative factor for decreasing carbapenem suscep-
tibility in non-fermentative bacteria such as Acinetobacter 
spp. and Pseudomonas aeruginosa. Th   e OXA enzymes in 
Acinetobacter  spp. are mainly chromosomally located, 
with little apparent transfer among strains [38]. Although 
these enzymes are structurally related to the older OXA 
β-lactamases, these new members of the OXA family 
have carbapenem-hydrolyzing activity. Because hydro-
lysis rates may be slow compared with other carba-
penemases, full carbapenem resistance may require an 
additional resistance mechanism such as a porin 
mutation or upregulated eﬄ   ux pump [39]. Importantly, 
carbapenemases within the OXA family have the ability 
to confer carbapenem resistance to organisms that may 
already have intrinsic resistance to multiple antibiotic 
classes [40]. Th   is is especially evident in the Acinetobacter 
spp. that have been identiﬁ  ed from soldiers and civilian 
populations returning from military duty in the Middle 
East [40].
Serine carbapenemases
Another emerging family of β-lactamases is the serine 
carbapenemase group (group 2f/class A). Th  is group of 
enzymes has the ability to hydrolyze most β-lactam 
antibiotics, including the carbapenems that are generally 
stable to hydrolysis by all other β-lactamases that have 
serine at the active site of the enzyme [11]. Early reports 
of this group of chromosomal enzymes were from single 
isolates of Enterobacteriaceae in the western US and 
London, followed by small outbreaks in Boston and 
Chicago a decade later [41]. Th  e ﬁ  rst plasmid-encoded 
serine carbapenemases in the KPC enzyme family were 
reported from the mid-Atlantic region of the US, again in 
single Klebsiella isolates (from the late 1990s) that were 
not immediately transferred within the reporting hospi-
tals [42]. However, KPC-producing K. pneumoniae 
strains soon began to spread into the New York City 
metropolitan area, then on to Israel, France, and now to 
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Europe, southeast Asia, and South America, with high 
clonality among and within geographical locations [43]. 
In addition, the genes encoding the KPC enzymes have 
spread into other Enterobacteriaceae as well as into P. 
aeruginosa and Acinetobacter spp. [41,44].
Metallo-β-lactamases
Metallo-β-lactamases, or MBLs (functional group 3/
molecular class B) belonging to another carbapenemase 
family, were initially recognized as species-speciﬁ  c  β-
lactamases with limited contributions to the overall 
resistance proﬁ   le in most medical centers [41]. Th  ese 
zinc-requiring chromosomal enzymes appeared in the 
same strain with other β-lactamases that generally had 
higher hydrolysis rates for penicillins and cephalosporins. 
Although these enzymes have relatively weak β-lactamase 
activity against all β-lactams except monobactams 
(aztreonam), their distinctive property is the ability to 
hydrolyze carbapenems [41]. Th  e MBLs were thereby 
responsible for carbapenem resistance in organisms such 
as Stenotrophomonas maltophilia, Aeromonas spp., and a 
small population of Bacteroides fragilis. However, the 
identiﬁ  cation of IMP-1, a plasmid-encoded MBL, in 1990 
[45] changed our perspective on the group 3 β-lactamases.
Plasmid-mediated carbapenem resistance has now 
become a serious clinical issue in parts of the world such 
as southern Europe, Japan, Brazil, and Asia. Th  e initial 
IMP-1 enzyme now belongs to a family with 26 variants; 
the VIM family of MBLs has 23 variants [6]. Th  ese 
enzymes were ﬁ  rst identiﬁ  ed in non-fermentative bacteria 
such as P. aeruginosa and  Acinetobacter  baumannii but 
have now spread to many of the Enterobacteriaceae, 
including Enterobacter spp., E. coli, C. freundii, Klebsiella 
spp., and S. marcescens [41]. Th  ey are frequently asso-
ciated with integrons (genetic dissemination systems) 
containing multiple antibiotic resistance deter  minants 
that are easily transferred among species. As with the 
species-speciﬁ   c MBLs, the plasmidic MBLs appear in 
organisms that almost always produce at least one other 
β-lactamase with an overlapping hydrolysis proﬁ  le. Th  us, 
it is possible that the MBL gene may be lost in the 
absence of speciﬁ  c antibiotic pressure, especially carba-
penem therapy.
Clinical response to β-lactamases
Nosocomial issues
When broad-spectrum cephalosporins were introduced 
into clinical practice, ESBL-producing Enterobacteriaceae 
began to arise proliﬁ  cally, resulting in the loss of these 
previously eﬀ  ective agents. In the late 20th century, many 
resistant Gram-negative bacteria were often treated with 
carbapenems as single therapeutic agents. At that time, it 
seemed that almost all β-lactamase-mediated resistances 
could be overcome by imipenem or meropenem. Th  ese 
antibiotics were not hydrolyzed by the AmpC cephalo-
sporinases or by ESBLs. Carbapenem monotherapy was 
the approach taken by some hospitals in which 
ceftazidime-resistant, ESBL-producing, K. pneumoniae 
isolates represented a majority of the Klebsiella isolates in 
the intensive care unit (ICU) [46]. For example, in a New 
York hospital [46] with a large outbreak of infections 
caused by ESBL-producing pathogens in the early 1990s, 
cephalosporin usage was reduced 80% throughout the 
hospital, accompanied by a 71% reduction in ceftazidime-
resistant Klebsiellae in the ICU. However, the collateral 
damage was that overuse of carbapenems resulted in a 
69% increase in imipenem-resistant P. aeruginosa [46] 
and in infections caused by imipenem-resistant Acineto-
bacter that were treatable only with polymyxin B or 
ampicillin-sulbactam [47]. Interestingly, a recent study 
from a New York ICU showed that strict infection control 
combined with routine rectal surveillance cultures was 
the most important factor associated with a reduction in 
carbapenem-resistant  K. pneumoniae isolates but not 
with the reduction of carbapenem-resistant P. aeruginosa 
or Acinetobacter spp.; antibiotic usage was not correlated 
with this reduction [48].
Today, we are seeing situations that are even more 
complex as multiple broad-spectrum β-lactamases are 
spreading throughout Gram-negative pathogens. Global 
dissemination of new β-lactamases is expected, with epi-
demiological characteristics easily traced with currently 
available molecular techniques. Recent studies have 
demon  strated the clonal appearance of a highly homo  ge-
neous CTX-M-15-producing E. coli strain that was 
present in both hospital and community isolates from 
eight countries in Europe, North America, and Asia [49]. 
Th  e  ﬁ  rst  KPC-2-producing  K. pneumoniae isolate 
reported in France was directly traced to a patient who 
had previously been treated in a New York City hospital 
[50]; subsequent analyses of KPC-producing K. pneumo-
niae isolates from the Centers for Disease Control and 
Prevention (CDC) identiﬁ  ed a major sequence type that 
accounts for over 70% of the CDC KPC isolates [43]. 
OXA carbapenemases have been identiﬁ  ed in multiple 
Acinetobacter spp. clones worldwide [40,51,52].
Organisms with multiple β-lactamases responsible for 
high-level resistance to most β-lactams are also appearing 
more frequently. A K. pneumoniae clinical isolate has 
been reported to produce eight diﬀ  erent β-lactamases, 
including at least one ESBL, an AmpC, and a KPC 
enzyme [53]. Th   e MBL VIM-1 was identiﬁ  ed in a Greek 
K. pneumoniae isolate that also produced the KPC-2 
carbapenemase [54]. Carbapenem-resistant Acineto bacter 
isolates have now been reported with both a VIM-2-like 
MBL as well as an OXA-23 carbapenemase in the same 
strain [55]. Th   ese organisms are resistant not only to all 
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Multidrug resistance has recently been reported in KPC-
producing K. pneumoniae in metropolitan New York City 
[56] and in MBL-producing isolates [57] because of 
plasmid-encoded resistance determinants that confer 
resistance to aminoglycosides, ﬂ  uoroquinolones,  tri-
metho  prim, sulphonamides, and chloramphenicol. Th  e 
Infectious Diseases Society of America (Arlington, VA, 
USA) made Gram-negative resistance a major focus in 
their 2009 list of ESKAPE pathogens that include 
multidrug-resistant K. pneumoniae, Acinetobacter spp., P. 
aeruginosa, and Enterobacter spp. [3].
On a more optimistic note, perhaps plasmid-encoded 
MBLs and their co-production with non-carbapenemases 
may not be the disaster some have envisioned. In the 
absence of a carbapenem-selective pressure in a patient, 
it is possible that the MBL gene may be lost, although 
that organism would still maintain its resistance proﬁ  le   
to other β-lactams. Th  is speculation is based on the 
experiences of Japan and Italy, two countries where 
plasmid-encoded MBLs were ﬁ  rst  identiﬁ   ed. In Japan 
and Italy, MBL genes that have spread countrywide after 
their initial reports have been responsible primarily for 
small sporadic outbreaks in these countries and have not 
been a continuous cause of carbapenem resistance 
throughout all Gram-negative species at a single medical 
center [58,59]. However, co-production of two 
carbapenemases, such as a VIM and KPC or a VIM and 
an OXA carbapenemase, may lead to much more serious 
consequences in which β-lactam antibiotics could never 
be useful.
Community reservoirs
Although the main focus has been on multidrug-resistant 
infections in the hospital setting, community sources for 
β-lactamase-mediated resistances are being reported 
more frequently. Community-acquired ESBLs in loca-
tions such as nursing homes or long-term health care 
resi  dences have been described for several years 
[31,32,60-62]. As one might expect, the even more 
deleterious plasmid-encoded carbapenemases are also 
being described in patients outside the hospital. Nine 
E. coli isolates producing the KPC-2 and KPC-3 carba-
penemases, enzymes most frequently found in 
K. pneumoniae strains, were identiﬁ  ed in seven nursing 
homes in the New York City area [63]. In Greece, a set of 
45 patients was identiﬁ  ed with community-onset urinary 
tract infections caused by VIM-2 MBL-producing 
P. aeruginosa isolates [64]. It is noteworthy that the ﬁ  rst 
CTX-M-producing  E. coli isolates in the US were 
identiﬁ  ed from sources that included a number of urinary 
tract isolates originating from outpatients [34]. Th  us, 
even if infection control procedures are instituted and 
strictly enforced in hospitals and medical centers, 
resistant Gram-negative pathogens have already been 
released into the community, where they can reside in 
relatively healthy people until challenged by changes in 
disease status, at which time they may become the 
causative pathogen for a new infection.
Conclusions
Resistance in Gram-negative pathogens is increasing at 
an alarming rate. New β-lactamases that are transferred 
among species on plasmids with multiple resistance 
factors are also being described as a continuing exercise. 
Th  e implications for therapeutic use of the workhorse 
β-lactam antibiotics are sobering. However, it is possible 
that some of these β-lactamases may exact a high price 
from the producing organism, especially when multiple 
β-lactamases are produced by a single strain. Small 
changes in therapeutic approaches may allow the ﬂ  ora to 
be altered within a medical center so that bacterial 
producers of ESBLs or KPCs or MBLs are only a small 
portion of the nosocomial ﬂ  ora and can be contained in 
isolated areas. Combination therapy with a β-lactamase 
inhibitor combination or a carbapenem, and at least one 
agent from another antibiotic class, may be eﬀ  ective 
against isolates that have decreased susceptibilities. Use 
of the maximally approved therapeutic doses should 
always be considered for serious infections when β-
lactam MICs are close to the susceptibility breakpoints. 
Finally, β-lactam antibiotics should not be used if their 
MICs are in the highly resistant category, particularly in a 
hospital known to have high levels of plasmid-encoded 
β-lactamases that are being transferred throughout the 
facility; it should be noted that this epidemiological infor-
mation may need to be determined with the assistance of 
a reference laboratory. With judicious use of antibiotics 
and strict infection control procedures, it may be possible 
to limit the eﬀ  ects of these newer β-lactamases until the 
time when new antibacterial agents are developed to 
counteract their eﬀ  ects.
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